Strides Pharma Science on Friday said that it has received establishment inspection report (EIR) from US Food and Drug Administration (USFDA) for its Bangalore facility, indicating closure of the inspection.
The US drug regulator had inspected the company's Bangalore facility from 5 December 2022 to 9 December 2022 and issued form 483 with 3 inspectional observations.
Based on the company's response to the observations and subsequent commitments, the USFDA had classified the inspection as VAI (voluntary action indicated).
The Bangalore-based facility is the company's largest manufacturing facility. The facility services the key regulated markets of the US, Europe, and Australia.
Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products.
On consolidated basis, the company reported net loss of Rs 80.03 crore in Q3 FY23 as compared with net loss of Rs 121.67 crore in Q3 FY22. Net sales rose 8.9% year on year to Rs 864.85 crore in Q3 FY23.
Shares of Strides Pharma Science were down 0.13% to Rs 298.40 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app